HK Kolmar's Patented Peptide Design Technology
HK Kolmar's patented skin cell-targeted peptide technology features a unique convergence of cosmetics and pharmaceutical technology. The idea for skin cell targeting DDS (drug delivery system) was born by fusing antibody-drug conjugates (ADCs) used in the pharmaceutical industry with skincare science. ADC technology maximizes efficient ingredient delivery, thereby amplifying the effect of the treatment.
Likewise, by separating 'problem cells' like wrinkles and delivering active ingredients to targeted cells, HK Kolmar's skin cell targeting technology absorbs damaged skin cells and delivers targeted active
ingredients with both speed and accuracy. The peptide technology binds itself to skin cell receptors, finds the damaged cells, and promptly dismantles them. HK Kolmar's cosmetic technology patent is the first in the industry to win the 'Triple Crown' of awards in Korea.
- HK Kolmar’s peptide technology absorbs damaged skin cells, and delivers targeted active ingredients with both speed and accuracy.
- The peptide technology binds itself to skin cell receptors, finds the damaged cells, and promptly dismantles them.
- The technology leverages ‘targeted therapy’, and pinpoints specific cells only.
